Based on real‐time visualization and quantitation of blood flow along with thrombus volume in cortical arterioles, we found that ozanimod, an FDA-approved drug to treat multiple sclerosis, can reduce thrombus volume and improve flow velocity when combined with subthrombolytic dose of tPA. The gene discussed is PLAT; the disease is multiple sclerosis.